IL178018A - Drug delivery system based on polyethylene vinylacetate copolymers - Google Patents
Drug delivery system based on polyethylene vinylacetate copolymersInfo
- Publication number
- IL178018A IL178018A IL178018A IL17801806A IL178018A IL 178018 A IL178018 A IL 178018A IL 178018 A IL178018 A IL 178018A IL 17801806 A IL17801806 A IL 17801806A IL 178018 A IL178018 A IL 178018A
- Authority
- IL
- Israel
- Prior art keywords
- delivery system
- drug delivery
- core
- skin
- copolymer
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title claims description 81
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 title claims description 80
- 150000001875 compounds Chemical class 0.000 claims description 100
- 230000000757 progestagenic effect Effects 0.000 claims description 62
- 229940117958 vinyl acetate Drugs 0.000 claims description 54
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 52
- 229920001577 copolymer Polymers 0.000 claims description 39
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims description 32
- 229920001169 thermoplastic Polymers 0.000 claims description 32
- 239000004416 thermosoftening plastic Substances 0.000 claims description 32
- 229960002941 etonogestrel Drugs 0.000 claims description 31
- 230000001076 estrogenic effect Effects 0.000 claims description 26
- 239000000835 fiber Substances 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 18
- 238000003860 storage Methods 0.000 claims description 13
- 238000002657 hormone replacement therapy Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 6
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 6
- 229960002568 ethinylestradiol Drugs 0.000 claims description 6
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 5
- 230000003637 steroidlike Effects 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 3
- -1 polyethylene Polymers 0.000 claims description 3
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 230000002254 contraceptive effect Effects 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 239000011162 core material Substances 0.000 description 66
- 230000032683 aging Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 238000001125 extrusion Methods 0.000 description 9
- 239000006213 vaginal ring Substances 0.000 description 9
- MXDOOIVQXATHKU-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXDOOIVQXATHKU-RYVPXURESA-N 0.000 description 8
- 229940044953 vaginal ring Drugs 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229940115044 nuvaring Drugs 0.000 description 6
- 239000000583 progesterone congener Substances 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000003466 welding Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 241000606161 Chlamydia Species 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229920002379 silicone rubber Polymers 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- QVLAWKAXOMEXPM-DICFDUPASA-N 1,1,1,2-tetrachloro-2,2-dideuterioethane Chemical compound [2H]C([2H])(Cl)C(Cl)(Cl)Cl QVLAWKAXOMEXPM-DICFDUPASA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ILAYIAGXTHKHNT-HVRMQOCCSA-N 4-[[4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile Chemical group CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)[14C]#N)=N1 ILAYIAGXTHKHNT-HVRMQOCCSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 229920003345 Elvax® Polymers 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920003351 Ultrathene® Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229950006497 dapivirine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960004845 drospirenone Drugs 0.000 description 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101215 | 2004-03-24 | ||
| PCT/EP2005/051189 WO2005089723A1 (en) | 2004-03-24 | 2005-03-16 | Drug delivery system based on polyethylene vinylacetate copolymers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL178018A0 IL178018A0 (en) | 2006-12-31 |
| IL178018A true IL178018A (en) | 2010-05-17 |
Family
ID=34928924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL178018A IL178018A (en) | 2004-03-24 | 2006-09-11 | Drug delivery system based on polyethylene vinylacetate copolymers |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8481079B2 (https=) |
| EP (1) | EP1732520B1 (https=) |
| JP (1) | JP2007530500A (https=) |
| CN (1) | CN100531800C (https=) |
| AR (1) | AR048185A1 (https=) |
| AT (1) | ATE434433T1 (https=) |
| AU (1) | AU2005224056B2 (https=) |
| BR (1) | BRPI0509146B8 (https=) |
| CA (1) | CA2559224C (https=) |
| DE (1) | DE602005015090D1 (https=) |
| ES (1) | ES2327247T3 (https=) |
| IL (1) | IL178018A (https=) |
| MX (1) | MXPA06010905A (https=) |
| MY (1) | MY142824A (https=) |
| PE (1) | PE20060127A1 (https=) |
| TW (1) | TWI290837B (https=) |
| WO (1) | WO2005089723A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1629844T1 (sl) † | 2004-07-13 | 2007-12-31 | Bayer Schering Pharma Oy | Sistem podaljšanega oddajanja s kontrolirano začetno dozo |
| MX2009005364A (es) * | 2006-11-20 | 2009-06-05 | Organon Nv | Sistema de suministro de farmaco con forma helicoidal. |
| MX2009005444A (es) * | 2006-11-22 | 2009-06-02 | Organon Nv | Sistema de suministro para un farmaco hidrofilico no esteroide no ionizado. |
| US8741329B2 (en) * | 2007-09-21 | 2014-06-03 | Merck Sharp & Dohme B.V. | Drug delivery system |
| TW200927141A (en) * | 2007-11-22 | 2009-07-01 | Bayer Schering Pharma Oy | Vaginal delivery system |
| EP2062568A1 (en) * | 2007-11-22 | 2009-05-27 | Bayer Schering Pharma Oy | Vaginal delivery system |
| PL2062569T3 (pl) * | 2007-11-22 | 2011-10-31 | Bayer Oy | Dopochwowy układ dostarczania leku |
| CA2755828A1 (en) | 2009-03-17 | 2010-09-23 | Intervet International B.V. | Zoo-technical drug delivery device |
| CA2755753A1 (en) * | 2009-03-17 | 2010-09-23 | Intervet International B.V. | Macrocyclic lactone drug delivery system |
| RU2648827C2 (ru) * | 2010-03-28 | 2018-03-28 | Эвестра, Инк. | Внутривлагалищное устройство для доставки лекарственного средства |
| US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
| EP2749286B1 (en) | 2011-08-26 | 2017-03-01 | Universidad De Santiago De Chile | Use of non-steroidal anti-inflammatory drugs meloxicam and piroxicam, administered intravaginally, for interruption of a woman's ovulation process |
| TW201332585A (zh) | 2012-02-14 | 2013-08-16 | Chemo Res S L | 核鞘藥物遞送裝置 |
| TR201808748T4 (tr) | 2012-09-03 | 2018-07-23 | Ecosea Farming S A | Hidrobiyolojik türlerin kültürü ve/veya korunmasına yönelik rezervuar-kafes daldırma sistemi. |
| US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
| US10596103B2 (en) | 2013-12-11 | 2020-03-24 | Merek Sharp & Dohme B.V. | Drug delivery system for delivery of anti-virals |
| US10413504B2 (en) * | 2013-12-11 | 2019-09-17 | Merck Sharp & Dohme Corp. | Intravaginal ring drug delivery system |
| CN104306380A (zh) * | 2014-09-18 | 2015-01-28 | 新疆特丰药业股份有限公司 | 结合雌激素和醋酸甲羟孕酮双层片及其制备方法 |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| US10406336B2 (en) | 2016-08-03 | 2019-09-10 | Neil S. Davey | Adjustable rate drug delivery implantable device |
| EP3395335A1 (en) * | 2017-04-24 | 2018-10-31 | Kern Pharma, S.L. | Vaginal ring for the simultaneous release of two active ingredients |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| US11690806B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| KR20260007295A (ko) | 2018-05-24 | 2026-01-13 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| CN113365634A (zh) * | 2018-12-11 | 2021-09-07 | 卢品公司 | 超低剂量雌激素组合的药物递送系统及其方法和用途 |
| WO2021068239A1 (zh) * | 2019-10-12 | 2021-04-15 | 国家卫生健康委科学技术研究所 | 用于黄体支持的阴道缓释给药系统及其制备方法与应用 |
| KR102159904B1 (ko) | 2020-04-24 | 2020-09-24 | 강경원 | 약물 방출 고리를 구비한 월경컵 |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| EP4507675A1 (en) * | 2022-04-14 | 2025-02-19 | Yale University | Nanoparticles and nanoparticle-releasing vaginal rings |
| CA3259928A1 (en) * | 2022-08-01 | 2024-02-08 | Lupin Inc. | DRUG DELIVERY SYSTEM FOR ULTRA-LOW DOSE ESTROGEN COMBINATIONS AND METHODS AND USES THEREOF |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3995633A (en) | 1975-12-02 | 1976-12-07 | The Procter & Gamble Company | Vaginal Medicament dispensing device |
| US3995634A (en) | 1975-12-02 | 1976-12-07 | The Procter & Gamble Company | Vaginal cavity dispensing means and method |
| US4237885A (en) | 1978-10-23 | 1980-12-09 | Alza Corporation | Delivery system with mated members for storing and releasing a plurality of beneficial agents |
| US4292965A (en) | 1978-12-29 | 1981-10-06 | The Population Council, Inc. | Intravaginal ring |
| DE3040978A1 (de) | 1980-10-28 | 1982-05-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Vaginalring |
| US4596576A (en) | 1984-10-12 | 1986-06-24 | Akzo N.V. | Release system for two or more active substances |
| WO1997002015A1 (en) | 1995-07-04 | 1997-01-23 | Akzo Nobel N.V. | Ring-shaped devices |
| IL123813A0 (en) * | 1997-04-11 | 1998-10-30 | Akzo Nobel Nv | Drug delivery system for two or more active substances |
| DK1037812T3 (da) | 1997-12-12 | 2003-11-24 | Akzo Nobel Nv | Emballage til vaginalring |
-
2005
- 2005-03-16 CN CNB2005800093236A patent/CN100531800C/zh not_active Expired - Fee Related
- 2005-03-16 US US10/594,104 patent/US8481079B2/en not_active Expired - Lifetime
- 2005-03-16 WO PCT/EP2005/051189 patent/WO2005089723A1/en not_active Ceased
- 2005-03-16 AT AT05717059T patent/ATE434433T1/de not_active IP Right Cessation
- 2005-03-16 MX MXPA06010905A patent/MXPA06010905A/es active IP Right Grant
- 2005-03-16 BR BRPI0509146A patent/BRPI0509146B8/pt not_active IP Right Cessation
- 2005-03-16 DE DE602005015090T patent/DE602005015090D1/de not_active Expired - Lifetime
- 2005-03-16 EP EP05717059A patent/EP1732520B1/en not_active Expired - Lifetime
- 2005-03-16 CA CA2559224A patent/CA2559224C/en not_active Expired - Lifetime
- 2005-03-16 TW TW094108065A patent/TWI290837B/zh not_active IP Right Cessation
- 2005-03-16 AU AU2005224056A patent/AU2005224056B2/en not_active Ceased
- 2005-03-16 JP JP2007504403A patent/JP2007530500A/ja not_active Withdrawn
- 2005-03-16 ES ES05717059T patent/ES2327247T3/es not_active Expired - Lifetime
- 2005-03-22 PE PE2005000327A patent/PE20060127A1/es not_active Application Discontinuation
- 2005-03-23 AR ARP050101144A patent/AR048185A1/es unknown
- 2005-03-24 MY MYPI20051277A patent/MY142824A/en unknown
-
2006
- 2006-09-11 IL IL178018A patent/IL178018A/en not_active IP Right Cessation
-
2013
- 2013-06-05 US US13/910,250 patent/US8808744B2/en not_active Expired - Lifetime
-
2014
- 2014-06-23 US US14/312,034 patent/US20140302115A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TWI290837B (en) | 2007-12-11 |
| EP1732520A1 (en) | 2006-12-20 |
| CN1933820A (zh) | 2007-03-21 |
| WO2005089723A1 (en) | 2005-09-29 |
| CA2559224A1 (en) | 2005-09-29 |
| EP1732520B1 (en) | 2009-06-24 |
| US20140302115A1 (en) | 2014-10-09 |
| AR048185A1 (es) | 2006-04-05 |
| JP2007530500A (ja) | 2007-11-01 |
| TW200536572A (en) | 2005-11-16 |
| AU2005224056A1 (en) | 2005-09-29 |
| BRPI0509146B8 (pt) | 2021-05-25 |
| CA2559224C (en) | 2011-12-13 |
| US8808744B2 (en) | 2014-08-19 |
| US8481079B2 (en) | 2013-07-09 |
| BRPI0509146A (pt) | 2007-09-04 |
| DE602005015090D1 (de) | 2009-08-06 |
| US20070141102A1 (en) | 2007-06-21 |
| BRPI0509146B1 (pt) | 2018-03-20 |
| ATE434433T1 (de) | 2009-07-15 |
| MXPA06010905A (es) | 2007-03-08 |
| IL178018A0 (en) | 2006-12-31 |
| MY142824A (en) | 2011-01-14 |
| ES2327247T3 (es) | 2009-10-27 |
| PE20060127A1 (es) | 2006-03-15 |
| AU2005224056B2 (en) | 2010-03-18 |
| CN100531800C (zh) | 2009-08-26 |
| US20130266632A1 (en) | 2013-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8808744B2 (en) | Drug delivery system based on polyethylene vinylacetate copolymers | |
| CA2524665C (en) | Drug delivery system | |
| US5989581A (en) | Drug delivery system for two or more active substances | |
| EA031802B1 (ru) | Система доставки лекарственных средств | |
| HK1084337B (en) | Drug delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |